Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2022

Open Access 01-12-2022 | NSCLC | Editorial

Targeted therapies for cancer

Authors: Zhijun Zhou, Min Li

Published in: BMC Medicine | Issue 1/2022

Login to get access

Abstract

Targeted therapy is the key for improving overall survival while decreasing the undesirable adverse effects of cancer treatment. Patients who received matched targeted therapies showed dramatically improved overall survival (OS) and progression-free survival (PFS) compared to those without matched therapies. However, each patient responds to targeted therapy differently due to their unique genomic profile. The discrepancy of treatment response between clinical trials and real-world clinical practice highlights an unmet need to develop tailored therapies for individual patients. The development of cutting-edge technologies, such as next-generation sequencing, has enabled us to identify more actionable targets. In this special issue of BMC Medicine, a collection of highly translational and clinical oncology papers presented a series of studies on targeted therapies for a variety of cancer types, aiming to bridge the gap between genomic testing and precision medicine and spark innovations on improving the efficacy of targeted therapies.
Literature
1.
Zhao S, Zhang Z, Zhan J, Zhao X, Chen X, Xiao L, et al. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. BMC Med. 2021;19(1):223.CrossRef
2.
Zhang Y, Zhang X, Zhang R, Xu Q, Yang H, Lizaso A, et al. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study. BMC Med. 2021;19(1):206.CrossRef
3.
Zou Z, Xing P, Hao X, Wang Y, Song X, Shan L, et al. Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study. BMC Med. 2022;20(1):12.CrossRef
4.
Ramagopalan S, Leahy TP, Ray J, Wilkinson S, Sammon C, Subbiah V. The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. BMC Med. 2021;19(1):209.CrossRef
5.
Zhang Y, Zeng L, Zhang X, Li Y, Liu L, Xu Q, et al. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC. BMC Med. 2021;19(1):245.CrossRef
6.
Mączyńska J, Raes F, Da Pieve C, Turnock S, Boult J, Hoebart J, et al. Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy. BMC Med. 2022;20(1):16.CrossRef
7.
Muller D, Mazzeo P, Koch R, Bosherz MS, Welter S, von Hammerstein-Equord A, et al. Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas. BMC Med. 2021;19(1):300.CrossRef
8.
Zhang Z, Zhang C, Luo Y, Wu P, Zhang G, Zeng Q, et al. m(6)A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer. BMC Med. 2021;19(1):284.CrossRef
9.
Hu J, Othmane B, Yu A, Li H, Cai Z, Chen X, et al. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer. BMC Med. 2021;19(1):289.CrossRef
Metadata
Title
Targeted therapies for cancer
Authors
Zhijun Zhou
Min Li
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-022-02287-3

Other articles of this Issue 1/2022

BMC Medicine 1/2022 Go to the issue

Research article

Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study

Research article

The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function

Research article

Longitudinal risk of maternal hospitalization for mental illness following preterm birth

Research article

Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status

Research article

Inequalities in the impact of COVID-19-associated disruptions on tuberculosis diagnosis by age and sex in 45 high TB burden countries

Research article

Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis